Table 1. General characteristics of the patients.
| Total patients n 790 | UAS7 ≤6 n 342 | UAS7 ≥7 n 448 | |
|---|---|---|---|
| Patient characteristics | |||
| Female sex * | 602 (76.2%) | 255 (74.5%) | 347 (77.4%) |
| Median age in years (SD range) * | 30 years (SD 11.6 range 68) | 32 (SD 13, range 68) | 29 (SD 10, range 66) |
| Age <49 years (%) | 735 (93%) | 311 (90.9%) | 424 (94.6%) |
| BMI * | 25 (SD 3.2 range 27) | 25 (SD 3.2 range 22.5) | 25 (SD 3.3 range 27) |
| Urticaria characteristics | |||
| CSU beginning (months)* | 24 (SD 41.2 range 58.6) | 21 (SD 50 range 58.6) | 33 (SD 33 range 35.8) |
| CIU * | 343 (43.4%) | 91 (26.6%) | 252 (56.2%) |
| Angioedema * | 343 (43.4%) | 91 | 252 |
| UAS7 baseline * | 26 (SD 7.8 range 35) | 22 (SD 8 range 34) | 26 (SD 7 range 35) |
| UAS7 final | 10 (SD 10 range 42) | 3 (SD 2 range 6) | 18 (SD 8 range 35) |
| Comorbidities | |||
| NSAIDs reaction* | 102 (12.9%) | 38 (11.1%) | 64 (14.2%) |
| Anxiety / Depression * | 252 (31.9%) | 81 (23.6%) | 171 (38.1%) |
| Autoimmune disease * | 118 (14.9%) | 53 (15.4%) | 65 (14.5%) |
| Paraclinical exams | |||
| Eosinophils * | 124 (SD 133 range 1001) | 125 (SD 141 range 1000) | 124 (SD 126 range 1001) |
| Anti-TIPO IgG * | 7.8 (SD 34.6 range 242) | 7.5 (SD 33.9 range 211) | 7.8 (SD 35.2 range 242) |
| C reactive protein * | 0,3 (SD 1.3 range 14,2) | 0.05 (SD 1.4 range 11.5) | 0.05 (SD 1.25 range 14.2) |
| Atopy* | 273 (34.6%) | 117 (34.2%) | 156 (34.8%) |
Preselected variables for the prediction model are indicated with *. Median, range, and SD are presented because they do not have a normal distribution. UAS7 final; Represents UAS7 after using antihistamines at a conventional dose or four times the conventional dose. CIU: Chronic inducible urticaria.